GE Healthcare Awarded Contract to Design New Plant-Based Biopharmaceutical Facility in Brazil - New facility for Bio-Manguinhos will use plant-based protein expression technology. - BioPharm

ADVERTISEMENT

GE Healthcare Awarded Contract to Design New Plant-Based Biopharmaceutical Facility in Brazil
New facility for Bio-Manguinhos will use plant-based protein expression technology.


GE Healthcare and iBio Inc. have signed a contract under which GE Healthcare will design a new plant-based multipurpose manufacturing facility for Bio-Manguinhos/Fiocruz in Brazil. The design project is the first contract for the global alliance between GE Healthcare and iBio, which was announced in 2012.

The alliance combines iBio’s plant-based manufacturing platform, iBioLaunch with GE Healthcare’s capabilities in process design and biopharmaceutical and vaccine manufacturing technologies. Bio-Manguinhos/Fiocruz is a manufacturer of immunobiologicals for public health needs, primarily to support programs of the Brazilian Ministry of Health. It has invested in the development of bioprocess technologies, such as iBioLaunch, through a codevelopment agreement with iBio and its research and development collaborator the Fraunhofer USA Center for Molecular Biotechnology, which will continue to play a role in advancing iBioLaunch. The iBioLaunch platform is a proprietary technology for the development and production of biologics using transient gene expression in unmodified green plants.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
AbbVie's Acquisition of Shire Could Save $8 Billion in Taxes
July 21, 2014
AbbVie to Acquire Shire for $54.7 Billion
July 18, 2014
AstraZeneca Reveals Design for New Global R&D Center and Corporate Headquarters
July 18, 2014
Particulate Matter Prompts Baxter's Recall of IV Solutions
July 17, 2014
Author Guidelines

Click here